Treatment of Parkinson’s Disease: Past, Present and Future - Miami, Florida, USA

March 21-22, 2014

Course Report

 

Course Faculty

Francisco Cardoso, MD, PhD, Director Federal University of Minas Gerais Movement Disorders Program and Professor of Neurology, Belo Horizonte, Brazil, MDS Secretary and MDS-PAS Chair Elect

Stanley Fahn, MD, H. Houston Merritt Professor of Neurology, Columbia University, Director Emeritus, Movement Disorder Division Neurological Institute, New York, NY, USA, MDS Past President and Honorary Member

Werner Poewe, MD, Director Innsbruck Medical University Department of Neurology, Innsbruck, Austria, MDS Past President and MDS-ES Past Chair



This novel course was organized to celebrate the importance of the development of Levodopa as a therapeutic option for Parkinson’s disease treatment by Francisco Cardoso, MD, PhD, Stanley Fahn, MD, and Werner Poewe, MD, addressed the historical aspects of development and introduction of Levodopa into clinical practice as well as the current uses for the drug.  In addition, the course covered other treatment options for Parkinson’s disease that are currently used, and treatments that may be options in the future.

The course was well attended with 150 clinicians, neurosurgeons, physician-assistants, nurses, physical therapists, fellows and others participating in the plenary lectures and breakout sessions.  During the two days there were 21 lectures presented and three breakout sessions focused on early stage cases, advanced stage non-motor cases and advanced stage motor cases. 

The international list of faculty included:

  • Angelo Antonini, MD, PhD • Venice, Italy
  • Francisco Cardoso, MD, PhD • Belo Horizonte, Brazil
  • Stanley Fahn, MD • New York, NY, USA
  • Susan Fox, MRCP(UK), PhD • Toronto, ON, Canada
  • Oscar Gershanik, MD • Buenos Aires, Argentina
  • Jennifer Goldman, MD, MS • Chicago, IL, USA
  • Horacio Kaufmann, MD • New York, NY, USA
  • Anthony Lang, OC, MD, FRCPC • Toronto, ON, Canada
  • Andrew Lees, MD, FRCP • London, United Kingdom
  • Peter LeWitt, MD • West Bloomfield, MI, USA
  • Elena Moro, MD, PhD • Grenoble, France
  • Giselle Petzinger, MD • Los Angeles, CA, USA
  • Werner Poewe, MD • Innsbruck, Austria
  • Ron Postuma, MD, MSc • Montreal, QC, Canada
  • Matthew Stern, MD • Philadelphia, PA, USA
  • Eduardo Tolosa, MD • Barcelona, Spain
     

As discussed during the course, the development of Levodopa has undoubtedly been the most important therapeutic breakthrough for treatment of PD; however, treatment options for the disease have advanced rapidly and likely will continue this way into the future.

Learning Objectives

At the conclusion of this activity, participants were able to accomplish the following:

  • Understand the history of development of levodopa
  • Recognize the complications of the use of levodopa in Parkinson's disease
  • Understand clinical and surgical management of complications of the use of levodopa in Parkinson's disease
  • Identify and discuss disease modifying strategies in PD
  • Understand experimental therapies in development for Parkinson's disease

     

This course is supported by unrestricted educational grants from:

                 

Top